Lesage Anne sold $81K of PHVS
Lesage Anne (Chief Early Development) sold 2,300 shares of Pharvaris N.V. (PHVS) at $35.12 on 2026-06-25 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
This is a disclosed open-market sale by an officer; absent accompanying corporate news, it mainly informs positioning/sentiment rather than fundamentals.
Market read
Traders may note insider selling, but the 10b5-1 structure makes it less actionable for directional trading.
What to watch
The filing does not disclose reasons for sale, and the post-transaction holdings (56,450 shares) suggest the insider did not exit the position.
Background
The article is an SEC EDGAR Form 4 insider transaction for Pharvaris N.V. (PHVS).
Ticker impact
SEC Form 4 shows officer Lesage Anne sold 2,300 PHVS shares for about $80.8K under a pre-arranged 10b5-1 plan.
Low likelihood of a sustained price move solely from this disclosure; any reaction is likely muted and short-lived.
The filing is a Form 4 insider transaction with an explicitly pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary sales.
Market effects
No clear sector read-through from a single small insider sale at a biotech/pharma issuer.
Minimal; disclosure is company-specific and not tied to broader regional catalysts.
Limited; no deal, trial, or regulatory event is disclosed.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations—so any negative tape reaction could be overdone.
Key entities
- issuerPharvaris N.V.
Company subject of the Form 4 insider transaction disclosure.
- insiderLesage Anne
Chief Early Development; sold shares under a pre-arranged 10b5-1 plan.
